Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes
出版年份 2017 全文链接
标题
Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes
作者
关键词
-
出版物
PHARMACOTHERAPY
Volume 37, Issue 8, Pages 927-943
出版商
Wiley
发表日期
2017-05-27
DOI
10.1002/phar.1962
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
- (2016) Julio Rosenstock et al. DIABETES CARE
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas
- (2016) M. M. Smits et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY
- (2016) Alan J. Garber et al. Endocrine Practice
- Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
- (2016) Daisuke Yabe et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis
- (2016) Bo Ahrén et al. Diabetes Therapy
- Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis
- (2016) Bo Ahrén et al. Diabetes Therapy
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
- (2015) Reinhard H. A. Becker et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
- (2015) Jennifer S. ten Kulve et al. DIABETOLOGIA
- Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study
- (2015) Y. Seino et al. HORMONE AND METABOLIC RESEARCH
- Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan
- (2015) Yutaka Seino et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials
- (2015) Kazuhiro Eto et al. Diabetology & Metabolic Syndrome
- Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials
- (2014) Markolf Hanefeld et al. ADVANCES IN THERAPY
- Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials
- (2014) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin
- (2014) Y. Seino et al. DIABETES OBESITY & METABOLISM
- Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes - a study in both people with type 2 diabetes and healthy subjects
- (2014) R. H. A. Becker et al. DIABETES OBESITY & METABOLISM
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)
- (2014) Chang Yu Pan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes
- (2014) Denis Raccah et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme
- (2014) Denis Raccah et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day
- (2014) Bo Ahrén et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
- (2014) Bernard Charbonnel et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
- (2014) Julio Rosenstock et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
- (2014) Yukiko Onishi et al. Journal of Diabetes Investigation
- Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
- (2013) Bo Ahrén et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
- (2013) M. Pinget et al. DIABETES OBESITY & METABOLISM
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
- (2013) C. Kapitza et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
- (2013) G. B. Bolli et al. DIABETIC MEDICINE
- A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes
- (2013) Justin J. Wilkins et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
- (2012) V. A. Fonseca et al. DIABETES CARE
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
- (2010) R. E. Ratner et al. DIABETIC MEDICINE
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started